FDAs plan to boost biosimilar drugs could stall at the patent office

Published: Friday, November 21, 2025 at 6:10 pm

FDA's Biosimilar Push Faces Patent Office Headwinds

The FDA is taking steps to streamline the approval process for biosimilar drugs, which are essentially generic versions of expensive biologic medications used to treat conditions like arthritis and cancer. These biosimilars have the potential to significantly lower healthcare costs, as they can be priced up to 90% less than their brand-name counterparts. The FDA's proposed changes aim to expedite the approval process, potentially saving companies up to $100 million per drug.

However, the U.S. Patent and Trademark Office is creating obstacles for biosimilar manufacturers. The patent office is making it more difficult for companies to challenge the numerous patents that brand-name drugmakers file to protect their products from competition. This is particularly concerning because biosimilar makers rely on challenging these patents to bring their products to market.

While the FDA's initiative is a positive development, industry officials say that the patent office's actions could undermine these efforts. The FDA's streamlining of regulations is often the least of the three major hurdles they face in marketing their products. The patent dance that occurs when biosimilar makers seek to launch competitor drugs can drag on for many years.

Biosimilars have the potential to significantly impact the healthcare landscape. Biologic drugs account for a substantial portion of the nation's medicine spending. The FDA's new rules would formalize recent practices aimed at speeding along approval for biosimilars.

BNN's Perspective:

While the FDA's efforts to facilitate biosimilar approvals are welcome, the conflicting actions of the patent office raise concerns. A coordinated approach is needed to ensure that the cost-saving potential of biosimilars is realized. This requires a balance between protecting innovation and promoting competition to benefit patients and the healthcare system.

Keywords: biosimilars, FDA, patents, drug prices, healthcare costs, biologic drugs, patent office, generic drugs, drug approvals, healthcare, prescription drugs, Humira, Keytruda, Enbrel, arthritis, cancer, drug costs

Full Story